New radiation boost aims to improve prostate cancer control

NCT ID NCT02016248

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is testing whether adding a short, high-dose radiation boost to standard radiation therapy can safely improve treatment for men with unfavorable localized prostate cancer. The boost is delivered non-invasively using stereotactic body radiotherapy (SBRT), similar to a needle-free version of brachytherapy. Researchers will track cancer control, side effects, and quality of life in 150 participants over time.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Stereotactic body radiotherapy (SBRT) boost
What this could lead to
If successful, this approach could offer a more effective, non-invasive way to treat unfavorable localized prostate cancer, potentially reducing the chance of cancer returning.
What could go wrong
This is a single-arm study with no comparison group, so it's unclear if the SBRT boost is better than standard treatment. Side effects like urinary or bowel problems are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROSTATE ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Long Beach Memorial Medical Center

    RECRUITING

    Long Beach, California, 90806, United States

  • Orange Coast Memorial Medical Center

    RECRUITING

    Fountain Valley, California, 92708, United States

  • Saddleback Memorial Medical Center

    RECRUITING

    Laguna Hills, California, 92653, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.